Are you involved in treating patients with triple negative breast cancer (TNBC)?
The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC. This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment.
This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.